Cencora (NYSE:COR) Given New $405.00 Price Target at Leerink Partners

Key Points

• Leerink Partners raised its Cencora price target to $405 from $388 and maintained an “outperform” rating, implying 19.15% upside from the stock’s then-current price.
• Cencora beat quarterly estimates, reporting adjusted EPS of $4.66 versus $4.58 expected and revenue of $88.35 billion versus $87.95 billion; revenue grew 5.5% year over year.
• Despite the earnings beat, shares fell $14.10 to $339.90 on Thursday. Analyst sentiment remained broadly positive, with a “Moderate Buy” consensus and an average target of $369.44.

Cencora (NYSE:COR - Get Free Report) had its target price lifted by stock analysts at Leerink Partners from $388.00 to $405.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Leerink Partners's price target indicates a potential upside of 19.15% from the stock's current price.

Several other research analysts have also issued reports on COR. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $382.00 to $390.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Morgan Stanley increased their price objective on Cencora from $346.00 to $377.00 and gave the company an "overweight" rating in a research report on Friday, October 30th. Wells Fargo & Company raised their price objective on Cencora from $331.00 to $395.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 11th. Evercore restated an "outperform" rating and issued a $350.00 target price (up from $330.00) on shares of Cencora in a report on Thursday, August 6th. Finally, Argus boosted their target price on Cencora from $340.00 to $380.00 and gave the stock a "buy" rating in a research report on Tuesday, October 20th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, Cencora presently has an average rating of "Moderate Buy" and a consensus price target of $369.44.

Cencora Price Performance

COR stock traded down $14.10 during trading hours on Thursday, hitting $339.90. 1,256,625 shares of the stock traded hands, compared to its average volume of 1,467,095. The stock has a 50-day simple moving average of $324.60 and a 200 day simple moving average of $317.44. The company has a market cap of $64.86 billion, a P/E ratio of 25.23, a P/E/G ratio of 1.74 and a beta of 0.58. Cencora has a one year low of $244.82 and a one year high of $377.54. The company has a current ratio of 0.93, a quick ratio of 0.58 and a debt-to-equity ratio of 3.53.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $4.66 earnings per share for the quarter, beating analysts' consensus estimates of $4.58 by $0.08. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The company had revenue of $88.35 billion during the quarter, compared to the consensus estimate of $87.95 billion. During the same period in the prior year, the company earned $3.84 EPS. Cencora's revenue was up 5.5% on a year-over-year basis. Equities analysts forecast that Cencora will post 17.88 earnings per share for the current year.

Insider Buying and Selling

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of Cencora stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the transaction, the executive vice president directly owned 19,455 shares in the company, valued at approximately $6,305,754.60. The trade was a 36.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.38% of the company's stock.

Institutional Trading of Cencora

Hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new position in Cencora in the second quarter valued at about $5,154,136,000. Bank of America Corp DE acquired a new position in shares of Cencora during the 2nd quarter worth about $1,056,625,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Cencora during the 2nd quarter worth about $483,772,000. Legal & General Group Plc bought a new stake in shares of Cencora in the 2nd quarter valued at about $339,556,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Cencora in the 2nd quarter valued at about $313,668,000. Hedge funds and other institutional investors own 97.52% of the company's stock.

Key Cencora News

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Fiscal Q4 adjusted EPS was $4.66, above the $4.58 consensus, while revenue of $88.4 billion also topped estimates and rose 5.5% year over year. Specialty-drug demand and expanding margins supported the results. Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand
• Positive Sentiment: Cencora set a fiscal 2027 adjusted EPS outlook of $19.40–$19.75; coverage characterized the forecast as an improvement. This signals continued expected earnings growth. Cencora outlines fiscal 2027 EPS outlook
• Positive Sentiment: The company raised its quarterly dividend 10% to $0.66 per share, a modest positive for shareholder returns. Cencora dividend announcement
• Neutral Sentiment: Cencora is reorganizing its reporting structure into two segments to improve focus and visibility. The strategic change could support execution, but its effect on results remains to be seen. Cencora announces new organizational and reporting structure
• Negative Sentiment: The earnings call also highlighted headwinds alongside specialty growth. That caution may be weighing on the shares despite the earnings beat; the supplied coverage does not specify the headwinds’ expected financial impact. Cencora earnings call highlights specialty growth and headwinds

Cencora Company Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.